$INKT
MiNK Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023063851 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.189M $1.800M
YoY Change 5.42% -61.3%
% of Gross Profit
Research & Development $3.311M $3.427M
YoY Change -43.04% -44.27%
% of Gross Profit
Depreciation & Amortization $53.57K $50.00K
YoY Change 41.23% 75.87%
% of Gross Profit
Operating Expenses $5.500M $3.427M
YoY Change -30.28% -44.27%
Operating Profit -$5.224M
YoY Change -34.6%
Interest Expense $41.53K $110.0K
YoY Change 18.33%
% of Operating Profit
Other Income/Expense, Net -$20.00 $8.00
YoY Change -100.02% -100.0%
Pretax Income -$5.459M -$5.120M
YoY Change -29.74% -19.14%
Income Tax
% Of Pretax Income
Net Earnings -$5.459M -$5.116M
YoY Change -29.74% -19.2%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15
Diluted Earnings Per Share -$0.16 -$0.15
COMMON SHARES
Basic Shares Outstanding 34.52M 34.51M
Diluted Shares Outstanding 34.50M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.367M $6.400M
YoY Change -82.85% -73.51%
Cash & Equivalents $3.367M $6.400M
Short-Term Investments
Other Short-Term Assets $231.1K $29.34K
YoY Change -50.87% -21.8%
Inventory
Prepaid Expenses $53.11K $41.96K
Receivables
Other Receivables
Total Short-Term Assets $3.598M $6.470M
YoY Change -82.37% -73.55%
LONG-TERM ASSETS
Property, Plant & Equipment $954.0K $991.5K
YoY Change -10.59% 23.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $954.0K $991.5K
YoY Change -10.58% 23.45%
TOTAL ASSETS
Total Short-Term Assets $3.598M $6.470M
Total Long-Term Assets $954.0K $991.5K
Total Assets $4.552M $7.462M
YoY Change -78.8% -70.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.912M $4.281M
YoY Change -32.82% -17.22%
Accrued Expenses $5.037M $3.847M
YoY Change 18.83% 35.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.40M $10.39M
YoY Change -10.1% -43.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.21M $63.98K
YoY Change 10227.33% 9.78%
Total Long-Term Liabilities $11.21M $63.98K
YoY Change 10227.33% 9.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.40M $10.39M
Total Long-Term Liabilities $11.21M $63.98K
Total Liabilities $22.61M $10.46M
YoY Change 76.74% -43.49%
SHAREHOLDERS EQUITY
Retained Earnings -$133.4M -$127.9M
YoY Change 20.29% 23.93%
Common Stock $115.8M $114.7M
YoY Change 4.46% 4.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$18.06M -$13.58M
YoY Change
Total Liabilities & Shareholders Equity $4.552M $7.462M
YoY Change -78.8% -70.46%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.459M -$5.116M
YoY Change -29.74% -19.2%
Depreciation, Depletion And Amortization $53.57K $50.00K
YoY Change 41.23% 75.87%
Cash From Operating Activities -$3.036M -$4.210M
YoY Change -31.48% -25.02%
INVESTING ACTIVITIES
Capital Expenditures $3.560K $20.00K
YoY Change -97.22% -133.44%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.560K -$20.00K
YoY Change -97.22% -66.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.830K 0.000
YoY Change 2472.73% -100.0%
NET CHANGE
Cash From Operating Activities -3.036M -4.210M
Cash From Investing Activities -3.560K -20.00K
Cash From Financing Activities 2.830K 0.000
Net Change In Cash -3.036M -4.230M
YoY Change -33.4% -25.45%
FREE CASH FLOW
Cash From Operating Activities -$3.036M -$4.210M
Capital Expenditures $3.560K $20.00K
Free Cash Flow -$3.039M -$4.230M
YoY Change -33.32% -23.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001840229
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40908
dei Entity Registrant Name
EntityRegistrantName
MiNK Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2142067
dei Entity Address Address Line1
EntityAddressAddressLine1
149 Fifth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10010
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
994-8250
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
INKT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
261203
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
298667
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
29341
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
470300
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34519540
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6398854
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19635725
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41959
CY2023Q3 us-gaap Assets Current
AssetsCurrent
6470154
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20404692
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
432507
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
283682
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
991458
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1066910
CY2023Q3 us-gaap Assets
Assets
7461612
CY2022Q4 us-gaap Assets
Assets
21471602
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4280894
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5823000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3846753
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4238555
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2266408
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2621611
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10394055
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12683166
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
63980
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
108500
CY2023Q3 inkt Due To Related Party
DueToRelatedParty
10584370
CY2022Q4 inkt Due To Related Party
DueToRelatedParty
9081239
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34519540
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33856428
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
345
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
339
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
114670386
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110829900
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-313188
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-292468
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127938336
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110939074
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-13580793
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-401303
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7461612
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21471602
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3427373
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6149778
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12179365
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17303205
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1796188
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1837571
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5241636
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5756864
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5223561
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7987349
us-gaap Operating Income Loss
OperatingIncomeLoss
-17421001
us-gaap Operating Income Loss
OperatingIncomeLoss
-23060069
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
107287
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
92960
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
421731
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
118488
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1562759
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2720108
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5116266
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6331630
us-gaap Net Income Loss
NetIncomeLoss
-16999262
us-gaap Net Income Loss
NetIncomeLoss
-20221473
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.6
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.6
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34497595
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34497595
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33757164
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33757164
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34293137
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34293137
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33627954
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33627954
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
88623
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1375464
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20720
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
546993
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5027643
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7707094
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17019982
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19674480
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-401303
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5686041
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-81335
CY2023Q1 inkt Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
45496
CY2023Q1 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
887811
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
33328
CY2023Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
346344
CY2023Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
379919
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4475781
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6196955
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
28008
CY2023Q2 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
864918
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
33347
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22020
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
187377
CY2023Q2 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
97718
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-9495364
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5116266
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-88623
CY2023Q3 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
906150
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
33114
CY2023Q3 inkt Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
2950
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-13580793
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23776469
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7777101
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
522771
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
689
CY2022Q1 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
741773
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
43733
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
17308334
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6112742
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1399686
CY2022Q2 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
796924
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3886
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
301
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
75
CY2022Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
136330
CY2022Q2 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
157194
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13689838
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6331630
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1375464
CY2022Q3 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
745880
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
27019
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
494
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6756137
us-gaap Profit Loss
ProfitLoss
-16999262
us-gaap Profit Loss
ProfitLoss
-20221473
us-gaap Depreciation
Depreciation
151045
us-gaap Depreciation
Depreciation
83816
us-gaap Share Based Compensation
ShareBasedCompensation
2758668
us-gaap Share Based Compensation
ShareBasedCompensation
2359215
inkt Gain On Forgiveness Of Liability
GainOnForgivenessOfLiability
266780
inkt Gain On Forgiveness Of Liability
GainOnForgivenessOfLiability
2790809
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-256668
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1544216
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2090462
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
760583
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1562717
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-2156714
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-2740954
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12726580
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14436321
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73561
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122208
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73561
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122208
inkt Proceeds From Employee Stock Purchases And Option Exercises
ProceedsFromEmployeeStockPurchasesAndOptionExercises
70466
inkt Proceeds From Employee Stock Purchases And Option Exercises
ProceedsFromEmployeeStockPurchasesAndOptionExercises
1484
inkt Purchase Of Treasury Shares To Satisfy Tax Withholdings
PurchaseOfTreasurySharesToSatisfyTaxWithholdings
477637
inkt Purchase Of Treasury Shares To Satisfy Tax Withholdings
PurchaseOfTreasurySharesToSatisfyTaxWithholdings
157194
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-407171
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-155710
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-29559
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-16002
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13236871
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14730241
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19635725
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38888828
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6398854
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24158587
us-gaap Interest Paid Net
InterestPaidNet
21439
us-gaap Interest Paid Net
InterestPaidNet
2546
inkt Purchases Of Plant And Equipment In Accounts Payable And Accrued Liabilities
PurchasesOfPlantAndEquipmentInAccountsPayableAndAccruedLiabilities
119629
us-gaap Stock Issued1
StockIssued1
1011358
us-gaap Stock Issued1
StockIssued1
293524
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127900000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6400000
CY2022Q4 inkt Accrued Research Services Current
AccruedResearchServicesCurrent
1681000
CY2023Q3 inkt Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
1884000
CY2022Q4 inkt Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
261000
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1138000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1655000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
496000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
642000
CY2023Q3 inkt Accrued Research Services Current
AccruedResearchServicesCurrent
327000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3847000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4239000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6148447
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
802535
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.26
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
105187
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
59995
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
14610
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.03
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6771190
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M7D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2303085
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6771190
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M7D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2303085
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3891563
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M14D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2303085
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.15
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4200000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
726163
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
765279
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
724656
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
2.16
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
766786
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.88
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
33000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
105187
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
120826
us-gaap Stock Issued During Period Shares Employee Benefit Plan
StockIssuedDuringPeriodSharesEmployeeBenefitPlan
603830
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
205879
inkt Stock Issued During Period Shares Employee Benefit Plan Net Of Shares Withheld For Taxes
StockIssuedDuringPeriodSharesEmployeeBenefitPlanNetOfSharesWithheldForTaxes
397951
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
939000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
773000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2759000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2359000
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(8) Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may currently be, or may become, a party to legal proceedings. While the Company currently believes that the ultimate outcome of any of these proceedings will not have a material adverse effect on its financial position, results of operations, or liquidity, litigation is subject to inherent uncertainty and consumes both cash and management attention.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>

Files In Submission

Name View Source Status
0000950170-23-063851-index-headers.html Edgar Link pending
0000950170-23-063851-index.html Edgar Link pending
0000950170-23-063851.txt Edgar Link pending
0000950170-23-063851-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
inkt-20230930.htm Edgar Link pending
inkt-20230930.xsd Edgar Link pending
inkt-ex31_1.htm Edgar Link pending
inkt-ex31_2.htm Edgar Link pending
inkt-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
inkt-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
inkt-20230930_lab.xml Edgar Link unprocessable
inkt-20230930_pre.xml Edgar Link unprocessable
inkt-20230930_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
inkt-20230930_cal.xml Edgar Link unprocessable